Literature DB >> 7795994

Faecal occult blood testing and colonoscopy in the surveillance of subjects at high risk of colorectal neoplasia.

M H Robinson1, O Kronborg, C B Williams, K Bostock, P S Rooney, L M Hunt, J D Hardcastle.   

Abstract

Colonoscopy is the established method of surveillance of subjects at high risk of developing colorectal neoplasia but the procedure is expensive, time consuming and occasionally hazardous. Faecal occult blood tests can be prepared at home and are cheap, simple and safe. Hemeselect is an immunological faecal occult blood test that is more sensitive for colorectal cancer than Haemoccult. The aim of this study was to determine the sensitivity of the Hemeselect test for asymptomatic colorectal neoplasia in subjects at high risk of the disease who were undergoing colonoscopy, thus assessing its suitability as an alternative means of screening high-risk groups. A total of 919 asymptomatic subjects were asked to complete Hemeselect tests. These were completed satisfactorily by 808 individuals (compliance rate 88 per cent) and were positive in 164 patients (20 per cent). At colonoscopy 11 cancers were detected in ten patients (seven Hemeselect positive) and 36 (16 Hemeselect positive) had at least one adenoma 1 cm or more in diameter. The test sensitivites of Hemeselect for carcinoma and large (1 cm or more) adenomas were 70 and 44 per cent respectively. In a subset of 417 subjects who also completed Haemoccult tests, the sensitivities were 33 and 18 per cent. Hemeselect specificity is 88 per cent compared with 98 per cent for Haemoccult. While the sensitivity of Hemeselect is higher than that of Haemoccult, it is still insufficient to replace colonoscopy in high-risk groups.

Entities:  

Mesh:

Year:  1995        PMID: 7795994     DOI: 10.1002/bjs.1800820310

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  10 in total

Review 1.  Effect of verification bias on the sensitivity of fecal occult blood testing: a meta-analysis.

Authors:  Alan S Rosman; Mark A Korsten
Journal:  J Gen Intern Med       Date:  2010-05-25       Impact factor: 5.128

2.  Comparison of three faecal occult blood tests in the detection of colorectal neoplasia.

Authors:  R L Hope; G Chu; A H Hope; R G Newcombe; P E Gillespie; S J Williams
Journal:  Gut       Date:  1996-11       Impact factor: 23.059

3.  Immunodiscrimination of colorectal neoplasia using MUC1 antibodies: discrepant findings in tissue versus stool.

Authors:  P J Limburg; D A Ahlquist; J A Gilbert; J J Harrington; G G Klee; P C Roche
Journal:  Dig Dis Sci       Date:  2000-03       Impact factor: 3.199

4.  Faecal calprotectin levels in a high risk population for colorectal neoplasia.

Authors:  O Kronborg; M Ugstad; P Fuglerud; B Johne; J Hardcastle; J H Scholefield; K Vellacott; V Moshakis; J R Reynolds
Journal:  Gut       Date:  2000-06       Impact factor: 23.059

5.  Stool DNA and occult blood testing for screen detection of colorectal neoplasia.

Authors:  David A Ahlquist; Daniel J Sargent; Charles L Loprinzi; Theodore R Levin; Douglas K Rex; Dennis J Ahnen; Kandice Knigge; M Peter Lance; Lawrence J Burgart; Stanley R Hamilton; James E Allison; Michael J Lawson; Mary E Devens; Jonathan J Harrington; Shauna L Hillman
Journal:  Ann Intern Med       Date:  2008-10-07       Impact factor: 25.391

6.  Faecal immunochemical test accuracy in patients referred for surveillance colonoscopy: a multi-centre cohort study.

Authors:  Jochim S Terhaar sive Droste; Sietze T van Turenhout; Frank A Oort; René W M van der Hulst; Vincent A Steeman; Usha Coblijn; Lisette van der Eem; Ruud Duijkers; Anneke A Bouman; Gerrit A Meijer; Annekatrien C T M Depla; Pieter Scholten; Ruud J L F Loffeld; Veerle M H Coupé; Chris J J Mulder
Journal:  BMC Gastroenterol       Date:  2012-07-24       Impact factor: 3.067

Review 7.  Screening for colorectal cancer by immunochemical fecal occult blood testing.

Authors:  H Saito
Journal:  Jpn J Cancer Res       Date:  1996-10

8.  Urinary Cysteine-Rich Protein 61 and Trefoil Factor 3 as Diagnostic Biomarkers for Colorectal Cancer.

Authors:  Takaya Shimura; Hiroyasu Iwasaki; Mika Kitagawa; Masahide Ebi; Tamaki Yamada; Tomonori Yamada; Takahito Katano; Hirotada Nisie; Yasuyuki Okamoto; Keiji Ozeki; Tsutomu Mizoshita; Hiromi Kataoka
Journal:  Transl Oncol       Date:  2019-01-03       Impact factor: 4.243

9.  Faecal immunochemical tests (FIT) versus colonoscopy for surveillance after screening and polypectomy: a diagnostic accuracy and cost-effectiveness study.

Authors:  Amanda J Cross; Kate Wooldrage; Emma C Robbins; Ines Kralj-Hans; Eilidh MacRae; Carolyn Piggott; Iain Stenson; Aaron Prendergast; Bhavita Patel; Kevin Pack; Rosemary Howe; Nicholas Swart; Julia Snowball; Stephen W Duffy; Stephen Morris; Christian von Wagner; Stephen P Halloran; Wendy S Atkin
Journal:  Gut       Date:  2018-12-11       Impact factor: 23.059

Review 10.  Advances in Fecal Occult Blood Tests: the FIT revolution.

Authors:  Graeme P Young; Erin L Symonds; James E Allison; Stephen R Cole; Callum G Fraser; Stephen P Halloran; Ernst J Kuipers; Helen E Seaman
Journal:  Dig Dis Sci       Date:  2014-12-10       Impact factor: 3.199

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.